FDA To Lift Ban On Ranbaxy Plant; Good News For Sun Compliance Push?
A US FDA ban on Sun Pharma’s Mohali site, a legacy Ranbaxy facility, is set to be lifted, marking a significant uptick in Sun’s compliance efforts and raising hopes of momentum at the Indian firm’s other tainted facilities.
You may also be interested in...
Sun Pharma, India’s biggest drug firm, slid into the red in the first quarter, hit by a hefty legal payout, regulatory woes and a dramatic drop in US sales, and company founder Dilip Shanghvi said while he expected a “gradual improvement” in performance, the outlook remained challenging.
Sun Pharma is believed to have tapped Davinder Singh, ex-Cipla technical director and veteran in the manufacturing space, as it tackles compliance-related challenges at its manufacturing sites.
Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.